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Aims: To study the frequency and intensity of depressive symptoms and associations with
physician resource utilisation following insulin initiation in patients with type 2 diabetes
mellitus.
Methods: SOLVE was a 24-week observational study. In this sub-analysis of data from Poland,
depressive symptoms were evaluated using the Patient Health Questionnaire (PHQ)-9.
Results: PHQ-9 was completed by 942 of 1169 patients (80.6%) at baseline, and 751 (64.2%) at
bothbaseline andﬁnal (24-week) visit. PHQ-9 scores indicateddepressive symptoms in 45.6%
(n=430) at baseline, and 27.2% (n=223) at ﬁnal visit. Mean PHQ-9 change was −2.38 [95% CI
−2.73, −2.02], p<0.001. Depressive symptoms at baseline (OR 6.32, p<0.001), microvascularDepressive symptoms
Depression
PHQ-9
HbA1c
Healthcare resource utilisation
disease (OR 2.45, p=0.016), number of physician contacts (OR 1.16, p=0.009), and change in
HbA1c (OR 0.60, p=0.025) were independently associated with moderate/severe depressive
symptoms at ﬁnal visit. Patients with more severe depressive symptoms spent more time
training to self-inject (p=0.0016), self-adjust (p=0.0023) and manage other aspects of insulin
delivery (p<0.0001). Patients with persistent depressive symptoms had more telephone
contacts and dose changes at ﬁnal visit than those without (both p<0.05).
Abbreviations: ACCORD, Action to Control Cardiovascular Risk in Diabetes; CI, conﬁdence interval; FBG, fasting blood glucose; HbA1c,
glycosylated haemoglobin A1c; HADS-D, Hospital Anxiety and Depression Scale; OR, odds ratio; OADs, oral antidiabetic drugs; PHQ-9,
Patient Health Questionnaire 9; SOLVE, Study of Once Daily LeVEmir; T2DM, type 2 diabetes mellitus.
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Conclusions: Depressive symptoms are common with type 2 diabetes and associated with
increased healthcare utilisation, reinforcing the need for holistic interdisciplinary manage-
ment approaches.
© 2015 Primary Care Diabetes Europe. Published by Elsevier Ltd.
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r. Introduction
atient involvement in diabetes disease management is crit-
cal to reaching agreed treatment goals; however, comorbid
sychological conditions, such as depressive symptoms and
iabetes distress, are common [1,2]. Depressive symptomsand
ajor depressive disorder are estimated to be twice as preva-
ent in patients with diabetes compared with patients without
iabetes [3]. Left unrecognised and untreated, even low lev-
ls of depressive symptoms can negatively affect self-care
ehaviour, which may ultimately impact glycaemic control [4]
nd contribute to poor health related quality of life and well-
eing [5]. These associations may be particularly important
n patients with complex or insulin-based treatment regi-
ens [6]. The presence of depressive symptoms has also been
eported as a barrier to insulin initiation [7].
Increased recognition and follow-up of comorbid depres-
ive symptoms in patients with diabetes is important to
itigate negative health outcomes associated with poor self-
are behaviour, such as missed medical appointments [4].
atients with diabetes and comorbid depressive symptoms
ave more frequent physician ofﬁce visits, hospital admis-
ions, and prescriptions, all of which contribute to an increase
nhealthcare costs of up to 65% [8]. Depressed patients are also
ore likely to switch, augment, and/or discontinue oral antidi-
betic drugs (OADs) than non-depressed patients [9]. Thus,
reatment aimedat improving patientwell-being and self-care
ay also improve healthcare utilisation.
The purpose of this sub-analysis of a large observational
tudy of insulin initiation in a cohort of patients with type 2
iabetes mellitus (T2DM) was to report on the prevalence of
epressive symptoms prior to and following insulin initiation.
urthermore, we identiﬁed demographic and clinical factors
ssociated with the severity and persistence of depressive
ymptomsand investigated the effect of depressive symptoms
n physician resource utilisation.
. Methods
OLVE (Study of Once Daily LeVEmir) is an observational study
f basal insulin initiation in people with T2DM treated with
ne or more OADs. The study was conducted in 10 countries
nd patient selection and study methodology has been previ-
usly described in detail [10,11]. The study was pre-registered
ith clinicaltrials.gov (NCT00825643 and NCT00740519) and
as approved by local ethics committees in each participat-ng country. In Poland, participating patients were managed
xclusively by specialists in accordance with national guide-
ines, which recommend specialist care for all T2DM patients
eceiving treatment with insulin.Patients were eligible for inclusion if they had been diag-
nosed with T2DM, were receiving treatment with one or more
OADs, and were being started on treatment with insulin
detemir. Children aged <18 years, patients who were pregnant
or breast-feeding or who intended to become pregnant and
patients deviating in the number of daily injections of
insulin detemir from once daily were excluded from the
study. Patients were observed at three time points: pre-
insulin (baseline), 12 weeks (interim visit), and 24 weeks
(ﬁnal visit). The study was non-interventional and there
was no imposed follow-up schedule. Instead, data were col-
lected at the visit closest to the protocol-deﬁned follow-up
interval. All treatment decisions including the decision to
initiate insulin detemir were at the discretion of the inves-
tigator.
The primary endpoint of the study was the incidence of
severe adverse drug reactions. Secondary endpoints included
severe hypoglycaemia (requiring third party assistance), any
minor hypoglycaemia (blood glucose <3.1mmol/L),minor noc-
turnal hypoglycaemia, change in glycosylated haemoglobin
A1c (HbA1c), fasting blood glucose (FBG), weight and bodymass
index. Physician resource utilisation was assessed by a ques-
tionnaire, and reports of ofﬁce visits and telephone contacts
at interim and ﬁnal visits.
This sub-analysis in Poland included the use of Patient
Health Questionnaire (PHQ)-9 at baseline and ﬁnal visits
(online Appendix). PHQ-9 is a nine-item depression scale,
which assesses symptoms and functional impairment over
the preceding 2 weeks. Each item scores 0–3 according to a
Likert scale; these scores are then summed as follows: none
(score <5),mild (score 5–9),moderate (score 10–14),moderately
severe (score 15–19), and severe (score ≥20) depressive symp-
toms. As such, PHQ-9 indicates whether or not a patient is
likely to have clinical depression and evaluates the impact
of depressive symptoms on patients’ social interactions at
home and in the work place. PHQ-9 is a validated tool for
identifying depressive symptoms and monitoring severity of
depression over time [12]; the questionnaire has also been
used as a screening tool in patients with chronic illnesses
including T2DM [13], and high symptom scores are associ-
ated with adverse outcomes [14]. According to the protocol,
any patient with suspected major clinical depression (i.e.,
PHQ-9 scores indicating moderately severe or severe depres-
sive symptoms) at baseline was referred to a psychiatrist for
follow-up.
Physician resource utilisation was assessed by recording
the time taken to train patients upon insulin initiation and the
number of telephone contacts, ofﬁce visits and dose changes
at interim and ﬁnal visits. Physicians recorded the amount of
time spent on training patients to self-inject and dose self-
 
Open access under CC BY-NC-ND license.adjust. Any training not related to these aspects was recorded
as other training time.
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Table 1 – Demography for all patients completing (PHQ+) and not completing (PHQ−) the PHQ-9 questionnaire at baseline.
Demographic PHQ+ cohort PHQ− cohort p-Value
N 942 (80.6%) 227 (19.4%)
Age (years) 60±10 60±10 0.5646
Male (%) 57.0 57.7 0.8477
Duration of diabetes (years) 7±5 8±4 0.3687
Previous medical history (%)
Macrovascular disease 37.4 38.6 0.7398
Microvascular disease 30.4 29.2 0.7300
HbA1c (%)
Pre-insulin 8.4±1.2 8.5±1.3 0.3713
Change −1.1 [−1.2; −1.0] −1.1 [−1.3; −0.8] 0.5583
FBG (mmol/L)
Pre-insulin 8.9±2.1 8.7±1.6 0.1251
Change −2.6 [−2.8; −2.5] −2.2 [−2.5; −2.0] 0.0137
FBG variability (mmol/L)
Pre-insulin 1.2±3.4 0.8±1.5 0.0253
Change −0.7 [−1.0; −0.4] −0.4 [−0.6; −0.1] 0.0838
Weight (kg)
Pre-insulin 87.0±17.6 86.8±14.5 0.8780
Change −1.2 [−1.4; −1.0] −1.5 [−1.9; −1.0] 0.3038
BMI
Pre-insulin 30.8±5.3 30.3±4.4 0.1488
Change −0.4 [−0.5; −0.3] −0.5 [−0.7; −0.4] 0.2462
Severe hypoglycaemia (events per patient year)
Pre-insulin 0.00 0.00 N/A
Change 0.00 0.00 N/A
Minor hypoglycaemia (events per patient year)
Pre-insulin 2.28±11.8 2.70±9.5 0.5691
Change +0.77±15.8 −1.87±10.1 0.0039
Minor nocturnal hypoglycaemia (events per patient year)
Pre-insulin 0.53±5.0 0.29±2.3 0.2868
Change −0.05±5.8 −0.20±2.5 0.5747
ody mPHQ, Patient Health Questionnaire; FBG, fasting blood glucose; BMI, b
2.1. Statistical analysis
All patients receiving at least one dose of insulin detemir
were included in the analysis of safety endpoints. Continu-
ous variables are described as mean± standard deviation, and
categorical variables are presented as frequency (percentage).
The incidence of hypoglycaemia is expressed as events per
patient year. Group comparisons were made using unpaired
t-tests for continuousvariables and theChi-Square test for cat-
egorical variables unless otherwise speciﬁed. The paired t-test
was used to compare continuous measurements at baseline
and ﬁnal visit (i.e., change frombaseline). Hypoglycaemia data
were analysed and compared using the Wilcoxon signed rank
test. The Jonckheere–Terpstra test was used to test for trends
between categories with an a priori ordering (i.e., none to
severe depressive symptoms) [15]. PHQ-9 data were analysed
as described above and previously [12]. To describe the asso-
ciations between depressive symptoms and measures during
the study or at ﬁnal visit, patients were grouped accordingly:
(1) no depressive symptoms at baseline or follow-up, (2) remis-
sion of depressive symptoms between baseline and follow-up,
(3) incident depressive symptoms at follow-up in patients
without depressive symptoms at baseline, and (4) persistent
depressive symptoms at baseline and follow-up.
Backward elimination logistic regressionmodelswere used
to evaluate predictors of depressive symptoms at baseline and
ﬁnal visit. The level of signiﬁcance was deﬁned as ˛=0.05. Allass index.
statistical analyses were performed using Statistical Analy-
sis Software v9.1 or newer (Cary, NC, USA). Imputation was
used to handle missing data in the regression models (online
Appendix).
3. Results
3.1. Patient demographics
In Poland, 1169 patients were included in the SOLVE study
after 21 patients had been excluded from the study for the
following reasons: no informed consent (n=16), no insulin
treatment (n=1), or both (n=4). PHQ-9 was completed by 942
of 1169 patients (80.6%) at baseline (Table 1). The majority
of patients completed PHQ-9 at both baseline and ﬁnal visit
(n=751, 64.2%; online Appendix). Signiﬁcant differences in
demographics were found at baseline between patients com-
pleting the PHQ-9 questionnaire (PHQ+) and those who did
not (PHQ−) in terms of change in FBG (−2.6mmol/L versus
−2.2mmol/L, p<0.05), baseline FBG variability (1.2mmol/L
versus 0.8mmol/L, p<0.05), and change in the rate of minor
hypoglycaemia (+0.8 versus −1.9 events per patient year,
p<0.005), respectively. There were no differences in age, sex,
duration of diabetes, weight, previous medical history of
macrovascular or microvascular complications, and baseline
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Table 2 – Depressive symptoms prior to insulin initiation (baseline) and after 24-weeks of insulin treatment (ﬁnal visit).
Baseline Final visit p-Value
PHQ severity
<0.0001
No symptoms 512 54.4% 597 72.8%
Mild 236 25.1% 178 21.7%
Moderate 132 14.0% 39 4.8%
Moderately severe 47 5.0% 6 0.7%
Severe 15 1.6% 0 0.0%
PHQ item 10a
<0.0001
No difﬁculty at all 407 43.7% 441 55.6%
Somewhat difﬁcult 446 47.9% 333 42.0%
Very difﬁcult 73 7.8% 17 2.1%
Extremely difﬁcult 5 0.5% 2 0.3%
a Item-10 of the PHQ-9 asks patients whether any of the symptoms listed have made it difﬁcult for patients to do work, take care of things at
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PHQ, Patient Health Questionnaire.
lycaemic control between PHQ+ and PHQ− groups. The rea-
ons for non-completion of the PHQ-9 were not recorded.
.2. Depression frequency and PHQ-9 scores
epressive symptoms were present in 45.6% (n=430) of
atients at baseline, and 27.2% (n=223) of patients at ﬁnal
isit. At baseline, the majority (n=236, 54.8%) of patients
ith depressive symptoms had mild symptoms, with mod-
rate/severe and severe symptoms present in 14.4% (n=62).
imilarly, at ﬁnal visit, symptoms were most commonly mild
n=178, 79.8%). The mean PHQ-9 score was 5.56±4.95 at base-
ine and 3.24±3.30 at ﬁnal visit, a change of −2.38 [95%
onﬁdence interval (CI) −2.73, −2.02], p<0.001. The severity of
epressive symptoms and the impact of symptoms on work,
aking care of things at home, or getting along with other peo-
le (item 10) are shown in Table 2..3. Multivariate predictors of depressive symptoms
ogistic regression analysis was performed to identify predic-
ors of moderate/severe depressive symptoms at baseline and
Table 3 – Results of elimination logistic regression models pred
baseline and ﬁnal visit.
Od
Depressive symptoms at baselinea
Covariates included: age, sex, diabetes duration, microvascular disease (ye
before insulin start (yes/no), HbA1c at baseline, weight at baseline
Female 1
Macrovascular disease 2
Baseline HbA1c (%) 1
Depressive symptoms at ﬁnal visita
Covariates included: age, sex, diabetes duration, microvascular disease (ye
insulin start and during study (both yes/no), change in HbA1c from baselin
telephone and ofﬁce contacts), and depressive symptoms at baseline
Microvascular disease 2
Depressive symptoms at baseline 6
Total number of physician contacts 1
Change in HbA1c (per % reduction) 0
a Refer to online Appendix for results of univariate analyses.ﬁnal visit (Table 3 andonlineAppendix). Female sex (odds ratio
[OR] 1.61 [95% CI 1.16–2.24], p=0.004), a previous history of
macrovascular disease (OR 2.14 [95% CI 1.53–2.99], p<0.001),
andhigher levels ofHbA1c (OR1.26 [95%CI 1.09–1.46], p=0.003),
were all independently associated with the reporting of mod-
erate/severe depressive symptoms at baseline.
At ﬁnal visit, reporting of moderate/severe depressive
symptoms was independently associated with moder-
ate/severe depressive symptoms at baseline (OR 6.32 [95%
CI 3.22–12.39], p<0.001), a previous history of microvascular
disease at baseline (OR 2.45 [95% CI 1.27–4.73], p=0.016), the
number of physician contacts during the study (OR1.16 [95%CI
1.04–1.30], p=0.009), and the change in HbA1c (OR 0.60 [95% CI
0.39–0.94], p=0.025). Themodel shows that for every 1% reduc-
tion in HbA1c relative to baseline, the risk of moderate/severe
depressive symptoms decreased by 40%.
3.4. Depressive symptoms and physician resource
utilisation
Training times according to depressive symptom severity
are shown in Table 4. The time spent training patients to
ictive of moderate to severe depressive symptoms at
ds ratio 95% conﬁdence limits
s/no), macrovascular disease (yes/no), hypoglycaemia
.61 1.16 2.24
.14 1.53 2.99
.26 1.09 1.46
s/no), macrovascular disease (yes/no), hypoglycaemia before
e to ﬁnal visit, weight loss of ≥1kg, contacts (sum of
.45 1.27 4.73
.32 3.22 12.39
.16 1.04 1.30
.60 0.39 0.94
350 pr imary care d iabetes 9 ( 2 0 1 5 ) 346–353
Table 4 – Training time according to the severity of depressive symptoms.
None Mild Moderate Moderately severe Severe p-Value
N 512 236 132 47 15
Training time (min)
±10
±10
±13Self-injection 15.2±10.6 14.8±9.2 17.4
Self-adjust dose 13.6±10.1 14.2±8.7 17.1
Other 21.6±14.5 20.8±14.1 24.3
self-inject and self-adjust insulin doses, and the management
of other aspects of insulin treatment increased as the severity
of depressive symptoms increased.
Table 5 shows the results of physician resource utilisa-
tion at 12 weeks and ﬁnal visit, according to the presence
and/or persistence of moderate/severe depressive symptoms.
Patients with moderate/severe depressive symptoms at both
baseline and ﬁnal visits (persistent depressive symptoms) had
a higher number of telephone contacts and dose changes at
ﬁnal visit than patients without moderate/severe depressive
symptoms.
4. Discussion
This sub-analysis of the SOLVE data shows that the use of
PHQ-9 in Poland identiﬁed a large proportion of T2DM patients
with depressive symptoms at the time of insulin initiation.
The majority of patients had mild depressive symptoms; how-
ever, 6.6% of all PHQ-9 responders had depressive symptoms
consistent with major clinical depression. Patients with mod-
erate/severe depressive symptoms at baseline had higher
pre-insulin HbA1c values. Moreover, the presence of mod-
erate/severe depressive symptoms at baseline was a strong
predictor of evidence of major clinical depressive symptoms
at ﬁnal visit. Such patients also appeared to have more fre-
quent contact with physicians, after adjusting for a number of
potential confounders including aspects of the patients’ pre-
vious medical history and clinical course during the 24-week
observational period.
PHQ-9 is one of several validated tools for identifying
and monitoring depressive symptoms in primary care [13,16].
However, several studies published while the SOLVE study
was ongoing have reported that the PHQ-9 categorises more
patients in the moderate to severe depression category than
another self-assessment measure, the Hospital Anxiety and
Depression Scale (HADS-D) [17–20]. Reddy et al. [20] also
reported that PHQ-9 response rates appeared to be inﬂuenced
by educational level, that there were more missing responses
to individual items on PHQ-9 than the HADS-D tool, and that
PHQ-9 may overestimate depression because it contains ques-
tions about symptoms common to diabetes.
Despite these controversies, the overall prevalence of
depressive symptoms reported here is consistent with that
reported previously. In a meta-analysis performed by Ali et al.
[21], the overall prevalence of depression in patients with
T2DM was 17.6%, with individual studies reporting preva-
lence from 6% to 52% depending on the patient cohort and
assessment method. This ﬁnding is consistent with the rate
of moderate/severe depressive symptoms (20.6% of patients
at baseline) in our study, taking into account differences in
the duration of diabetes, level of glycaemic control, prevalence.1 20.0±15.4 21.2±15.2 0.0016
.3 17.0±7.9 15.6±10.1 0.0023
.4 32.2±18.5 23.5±16.7 <0.0001
of macrovascular and microvascular disease, and degree of
obesity,which are known to be correlates for depression india-
betes [22,23]. Severity of depression inpatientswithdiabetes is
known to ﬂuctuate over time [24]. This ﬂuctuation may occur
for a variety of reasons related or unrelated to the disease;
however, associations between depressive symptomatology
and glycaemic control, weight, and hypoglycaemia have been
reported.
The relationship between depressive symptoms and gly-
caemic control also remains controversial, with results from
several large studies showing contrasting results [25–27].
These differences may be explained by confounding factors
such as the use of insulin and the frequency of healthcare con-
tact [28], the natural history and underlying cause of comorbid
depression in diabetes [29], and the diagnostic overlap with
other psychological problems such as anxiety and diabetes
distress [30]. Papelbaum et al. [31] reported higher levels of
HbA1c in T2DM patients with depression than those with-
out mood disorder; however, HbA1c levels were not higher in
patients with a history of depression who were not depressed
at the time of clinical evaluation. A study by Aikens et al. [32],
which assessed depressive symptoms using PHQ-9 found that
depressive symptoms were not prospectively associated with
6-month glycaemic control; however, among insulin users,
glycaemic control was predictive of depressive symptoms.
These results suggest that the direction of association is that
of glycaemic control on depressive symptoms, which may be
mediated by hyperglycaemic and hypoglycaemic symptoms
[33–36]. The Whitehall II study reported higher depression
scores for patients with both the lowest and highest blood
glucose levels (both fasting and post-prandial), with the low-
est depression scores in the range of normoglycaemia [35].
Associations between HbA1c and moderate/severe depres-
sive symptoms in our study are consistent with these earlier
reports.
Similarly, associations between moderate/severe depres-
sive symptoms and both macrovascular and microvascular
disease have been reported [37,38]. Recently published data
from the ACCORD (Action to Control Cardiovascular Risk in
Diabetes)Health-RelatedQuality of Life sub-studyalso suggest
a possible association between depression and an increased
risk of macrovascular events among adults with T2DM already
at high risk for cardiovascular events [14]. Microvascular and
macrovascular disease might reﬂect the overall psychologi-
cal burden of diabetes as well as being surrogate markers
of previously poorly controlled disease [38]. Alternatively, the
susceptibility to developing depression may be a consequence
and an early manifestation of cerebral microvascular disease
[39,40]. Another theory is that patientswith depressionmay be
predisposed to poor control and the development of microvas-
cular and macrovascular complications as a result of poor
self-care behaviour [41].
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Table 5 – Physician resource utilisation at 12-weeks and ﬁnal (24-weeks) visit, according to the presence and/or
persistence of moderate/severe depressive symptoms.
No depressive
symptoms at
baseline or
ﬁnal visit
Depressive
symptoms at
baseline only
Depressive
symptoms at
ﬁnal visit only
Depressive
symptoms at
baseline and
ﬁnal visit
N 579 130 18 24
Ofﬁce visits
12-weeks 1.32 [1.22; 1.41] 1.29 [1.10; 1.48] 1.28 [0.56; 2.00] 1.36 [0.82; 1.90]
24-weeks 1.04 [0.96; 1.13] 0.89 [0.74; 1.05] 0.88 [0.44; 1.32] 1.43 [0.80; 2.07]
Telephone contacts
12-weeks 0.57 [0.49; 0.66] 0.61 [0.45; 0.76] 0.75 [0.29; 1.21] 1.04 [0.56; 1.52]*
24-weeks 0.43 [0.37; 0.50] 0.49 [0.35; 0.62] 1.07 [0.53; 1.60]* 1.22 [0.68; 1.75]*
Number of dose changes
12-weeks 1.54 [1.42; 1.66] 1.48 [1.31; 1.65] 1.18 [0.52; 1.84] 1.43 [0.99; 1.87]
3; 1.3 *
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w24-weeks 1.24 [1.13; 1.35] 1.19 [1.0
∗ p<0.05 compared to reference group: no depressive symptoms at b
Weight (in the presence or absence of diabetes mellitus)
42–44] and hypoglycaemia [45] have also been associated
ith depression. In our study, neither weight loss nor the
resence of hypoglycaemia was identiﬁed as an independent
redictor of moderate/severe depressive symptoms during
ollow-up. The reasons for this are not known, but may have
een because of the relatively small absolute change in weight
elative to the aforementioned studies, and the relatively
ow number of reported hypoglycaemic events. Notably, the
requency of healthcare contact (adjusted for in our analy-
is) may have been overlooked as an important confounder
n randomised studies comparing more intensive treatment
ith usual care [46,47]. Graco et al. [28] found that glycaemia
mproved more in patients who were seen earlier in their dis-
ase course and were managed more intensively, regardless
f their psychometric status.
Patients with moderate/severe depressive symptoms had
ncreased resourceutilisation as represented by the total num-
er of physician contacts (Table 5). Patients with chronic
iseases account for approximately 26% of out-of-hours calls
o primary healthcare services – the third most frequent
ingle diagnosis being diabetes after lung disease and can-
er [48]. In randomised clinical trials, contact frequency is
ighly correlated with improvement in glycaemic control in
nsulin-treated patients with T2DM [49]. However, in real-life
bservational studies, increased telephone and ofﬁce visits
re likely to result in other healthcare costs in addition to
hose associated with healthcare personnel time. An evalua-
ion of diabetes disease management programmes found that
emberswho receivedmore telephone contact demonstrated
0–24% higher low-density lipoprotein and HbA1c testing rates
han members who received mailings alone [50].
Assuming that resource utilisation is a surrogate marker
or self-efﬁcacy, the ﬁndings of our study suggest that
hatever the causal relationship betweendepression and self-
fﬁcacy, resolving depressive symptoms may lead to lower
evels of physician resource utilisation. However, resource
tilisation may not necessarily be patient initiated. Having
dentiﬁed depressive symptoms, physicians may be more
oncerned about patient welfare and therefore plan more fre-
uent contact. Last, since the insulin doses at the ﬁnal visit
ere still relatively low, and many patients had not reached4] 1.11 [0.65; 1.57] 1.80 [1.35; 2.25]
e or ﬁnal visit.
target HbA1c levels of <7.0% (<53mmol/mol), it could be argued
that both patients with and without depressive symptoms
may have beneﬁted from more intensive follow-up and dose
adjustment.
Our study has a number of important limitations and
results should be interpreted as hypothesis generating. The
study was observational; therefore, it is not possible to
attribute the improvement in depressive symptoms to any
speciﬁc intervention or treatment effect. Neither is it possi-
ble to exclude a placebo effect of initiating a new treatment
and participating in a clinical study. Notably, only two of
the countries participating in the SOLVE study (Israel and
Poland) performed the PHQ-9 assessment. The small num-
ber of responses and the risk of selection bias meant that
data from Israel was excluded from this analysis. In addi-
tion, imputation of missing data assumes that the loss of data
was completely at random.Thehealthcare resourceutilisation
questionnaires used in our study have not been previously val-
idated; however, a part of the assessment did include direct
measures of healthcare utilisation such as duration of time
spent training patients in various aspects of insulin treatment
and patient contact frequency. Last, the PHQ-9 scale alone
cannot be used to make a ﬁrm diagnosis of depression, but
it remains a well-researched and validated tool for identifying
and monitoring depressive symptoms.
5. Conclusion
Depressive symptoms are common in patients with T2DM
in Poland, and are associated with female sex, a history of
macrovascular disease, and evidence of poor glycaemic con-
trol. Mean PHQ-9 scores improved during the course of the
24-week observational period, which may be associated with
an improvement in glycaemic control anddiabetes symptoms.
Incident and persistent depressive symptoms were associ-
ated with increased healthcare utilisation. To the best of our
knowledge, an improvement in depressive symptoms despite
of insulin initiation has not been reported previously. Given
the complexities involved in managing depressive symptoms
in people with T2DM, patients should receive holistic care
from an interdisciplinary team.
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